1. Home
  2. DVS vs PEPG Comparison

DVS vs PEPG Comparison

Compare DVS & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DVS

Dolly Varden Silver Corporation

HOLD

Current Price

$3.24

Market Cap

446.5M

Sector

N/A

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$5.16

Market Cap

425.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVS
PEPG
Founded
2011
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
446.5M
425.1M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
DVS
PEPG
Price
$3.24
$5.16
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.67
AVG Volume (30 Days)
1.2M
616.8K
Earning Date
03-16-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$0.89
52 Week High
$5.93
$7.80

Technical Indicators

Market Signals
Indicator
DVS
PEPG
Relative Strength Index (RSI) 25.98 40.53
Support Level N/A $5.04
Resistance Level $3.96 $5.50
Average True Range (ATR) 0.26 0.56
MACD -0.13 -0.15
Stochastic Oscillator 0.82 10.05

Price Performance

Historical Comparison
DVS
PEPG

About DVS Dolly Varden Silver Corporation

Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: